Últimas noticias sobre CME Group (NASDAQ:CME) Bolsa

CME GROUP INC

CME Group

CME Gr

Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.

Xrp,Logo,And,Coins,With,Focal,Length,Effect

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$XRP

Ripple (CRYPTO: XRP) cotiza actualmente a 2,35 dólares, lo que implica un crecimiento del 0,14 % en un día. Tras una caída de más del 10 % la semana pasada, Ripple logró registrar una ganancia del 10,50 % en un mes.

Ripple (XRP) sube tras debutar en CME: ¿Qué significa para su precio y futuro regulatorio?

Golden,Xrp,Coins,Are,Displayed,In,Front,Of,Green,And

News

Markets

Los traders de derivados apostaron agresivamente por un aumento del precio de XRP (CRYPTO: XRP) tras el anuncio de los contratos de futuros de la criptomoneda en CME Group Inc. (NASDAQ:CME) el jueves.

XRP conquista los traders: Aumentan posiciones largas tras futuros de CME y posible ETF

Long Ideas

Media

Trading Ideas

$BTC

$ETH

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

TOST

En el programa de la CNBC “Halftime Report Final Trades”, Joshua Brown de Ritholtz Wealth Management nombró Toast, Inc. (NYSE:TOST) como su operación recomendada.

Acciones recomendadas en CNBC: Toast, CME Group y Goldman Sachs destacan

CME Group Inc

COMPUTER ENGNR&CONSLTNG by Computer Engineering & Consulting Ltd

Computer Engineering & Consulting Ltd

CHINA MEIDONG AUTO HLDGS by China Meidong Auto Hldgs

China MeiDong Auto Holdings Ltd

CM ENERGY TECH CO LTD by CM ENERGY TECH CO LTD

CM Energy Tech Co Ltd

CREO MED GROUP LTD by CREO MED GROUP LTD.

Creo Medical Group PLC

CoinMerge (BEP-20)

CMONEY INC by cMoney, Inc.

CME Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CME#NYSE">CME</a>) short percent of float has fallen 9.59% since its last report. The company recently reported that it has 4.73 million shares sold short, which is 1.32% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.34 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>CME Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753714874_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CME Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing CME Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, CME Group's peer group average for short interest as a percentage of float is 5.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About CME Group?

7 analysts have shared their evaluations of CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $296.57, a high estimate of $305.00, and a low estimate of $275.00. This upward trend is apparent, with the current average reflecting a 2.93% increase from the previous average price target of $288.14.
<img src="https://www.benzinga.com/files/images/story/2025/1753390834_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of CME Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$305.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$303.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$298.00</td>
<td>$299.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$296.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$299.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$275.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$282.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CME Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CME Group compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of CME Group's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CME Group's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CME/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CME Group analyst ratings.</a>
<h2>Unveiling the Story Behind CME Group</h2>
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&amp;P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&amp;P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
<h3>CME Group's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining CME Group's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.38% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 57.49%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): CME Group's ROE excels beyond industry benchmarks, reaching 3.53%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.64%, the company showcases effective utilization of assets.
Debt Management: CME Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.13.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down CME Group: 7 Analysts Share Their Views

UBS analyst Alex Kramm downgrades CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) from Buy to Neutral and maintains the price target from $305 to $305.

Downgrades

Price Target

UBS Downgrades CME Group to Neutral, Maintains Price Target to $305

Oppenheimer analyst Owen Lau maintains CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) with a Outperform and raises the price target from $300 to $303.

Oppenheimer Maintains Outperform on CME Group, Raises Price Target to $303

Barclays analyst Benjamin Budish maintains CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) with a Equal-Weight and lowers the price target from $299 to $298.

Barclays Maintains Equal-Weight on CME Group, Lowers Price Target to $298

A wave of U.S. trade deals with key allies over the past 24 hours reignited Wall Street's rally and boosted investor risk <a href="https://www.benzinga.com/markets">appetite across global markets.</a>
President Donald Trump announced agreements with the Philippines, Indonesia and—most significantly—Japan, while the <a href="https://www.ft.com/content/460b7784-88d7-4324-9e4d-dc9692d15e72">Financial Times</a> reported that a U.S.-EU trade deal is imminent, expected to mirror the Tokyo framework.
The U.S.-Japan pact raises the baseline tariff on Japanese goods to 15% from 10%, sidestepping the previously threatened 25% level. Tariffs on Japanese autos have been cut from 25% to 15%. In return, Japan committed to investing $550 billion in the U.S. and easing access to American agricultural and industrial goods.
Markets cheered the progress. The S&amp;P 500 rose 0.5% to a new record high of 6,350, while the Dow Jones Industrial Average surged nearly 1%, or 450 points, nearing its own record. Small-cap stocks led the charge, with the Russell 2000 also jumping 1.0% to its highest level since February.
International equities soared even more. The iShares MSCI Japan Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWJ#NYSE">EWJ</a>) rallied 4.9% to an all-time high, the SPDR DJ Euro STOXX 50 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FEZ#NYSE">FEZ</a>) climbed nearly 2%, and the iShares MSCI Mexico ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWW#NYSE">EWW</a>) gained 2.1%.
As optimism over global trade thawed investor caution, demand for safe-haven assets dropped. Gold slid 1.4% to $3,383 per ounce, while silver dipped 0.3%. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell 2% to $117,760. 
Next up: a major earnings test. Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), ServiceNow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) and IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) are all set to report results after Wednesday's close.
<h2 class="wp-block-heading">Wednesday&#8217;s Performance Of US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>% Chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,272.31</td>
<td>1.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,892.90</td>
<td>0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,340.17</td>
<td>0.5%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>23,077.71</td>
<td>0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:40 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) rose 0.5% to $580.89.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.9% to $448.95.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;held steady at $561.44.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 1.1% to $225.66.</li>
<li>The&nbsp;Industrials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) outperformed, up 1.8%; the&nbsp;Utilities&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.8%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stocks Movers</h3>
<ul class="wp-block-list">
<li>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) soared 13% after beating the Street&#8217;s estimates last quarter.</li>
</ul>
Other stocks reacting to earnings reports included:
<ul class="wp-block-list">
<li>Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) down 3.54%</li>
<li>Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) down 11.80%</li>
<li>Boston Scientific Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) up 3.94%</li>
<li>NextEra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>) down 6.62%</li>
<li>Amphenol Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) up 3.15%</li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) up 1.32%</li>
<li>Moody's Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) up 2.14%</li>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) up 2.30%</li>
<li>General Dynamics Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) up 6.47%</li>
<li>Fiserv Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FI#NASDAQ">FI</a>) down 16.10%</li>
<li>Infosys Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>) up 1.66%</li>
<li>Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) down 1.84%</li>
<li>Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) down 2.04%</li>
<li>TE Connectivity plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) up 10.30%</li>
<li>CoStar Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) up 6.34%</li>
<li>Otis Worldwide Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>) down 10.32%</li>
<li>Teledyne Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) down 3.76%</li>
<li>Lennox International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) up 8.84%</li>
<li>Northern Trust Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>) down 3.53%</li>
<li>Rogers Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>) up 0.29%</li>
<li>East West Bancorp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) down 2.16%</li>
<li>Mr. Cooper Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) up 0.90%</li>
<li>Hasbro Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) down 0.73%</li>
<li>Lamb Weston Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) up 16.08%</li>
</ul>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46557704/trump-america-first-agenda-ai-industrial-stocks-defense-sector">Trump&#8217;s Sledgehammer Policies Have Ignited Wall Street&#8217;s Hottest Trade—And It&#8217;s Not AI </a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Government

Large Cap

Macro Economic Events

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Emerging Market ETFs

Commodities

Economics

Tech

ETFs

COOP

CSGP

SPDR Dow Jones Industrial Average ETF Trust

EWBC

GOOGL

INFY

ISRG

NTRS

OTIS

TSLA

Stocks Jump On Trump's Trade Deal Deluge Ahead Of Big Tech Earnings: What's Moving Markets Wednesday?

Earnings

CME Group Avg Daily Volume 30.2M Contracts, Up 16% YoY

CME Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) reported quarterly earnings of $2.96 per share which missed the analyst consensus estimate of $2.98 by 0.6 percent. This is a 15.62 percent increase over earnings of $2.56 per share from the same period last year. The company reported quarterly sales of $1.69 billion which missed the analyst consensus estimate of $1.71 billion by 0.85 percent. This is a 10.37 percent increase over sales of $1.53 billion the same period last year.

Earnings Misses

CME Gr Q2 Adj. EPS $2.96 Misses $2.98 Estimate, Sales $1.69B Miss $1.71B Estimate

AMTB

ASGN

BANC

BPOP

BRKL

CADE

CBAN

CHDN

CSBR

CVBF

CVLG

EGBN

EPRT

EQNR

ESRT

First Trust Advantage Preferred Income Fund

FRME

FSBC

GLPG

GOOG

GSHD

HBNC

HCSG

ICLR

INBK

KALU

MTAL

NTST

NVEC

ORLY

OTLY

OXLC

PLXS

PTEN

QCRH

RBBN

RELL

SEIC

SIGI

Earnings Scheduled For July 23, 2025

CME Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-07-23. Here's a quick overview of what investors should know before the release.
Analysts are estimating that CME Gr will report an earnings per share (EPS) of $2.95.
CME Gr bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.01, leading to a 0.68% increase in the share price the following trading session.
Here's a look at CME Gr's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.79</td>
<td>2.45</td>
<td>2.65</td>
<td>2.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.80</td>
<td>2.52</td>
<td>2.68</td>
<td>2.56</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>0.0%</td>
<td>1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753196505_0.png" alt="eps graph" />
<h3>CME Gr Share Price Analysis</h3>
Shares of CME Gr were trading at $275.0 as of July 21. Over the last 52-week period, shares are up 39.36%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Take on CME Gr</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on CME Gr.
Analysts have provided CME Gr with 10 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $282.8, suggesting a potential 2.84% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Intercontinental Exchange, Coinbase Global and Moodys, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Intercontinental Exchange, with an average 1-year price target of $199.5, suggesting a potential 27.45% downside.</li>
<li>Analysts currently favor an Buy trajectory for Coinbase Global, with an average 1-year price target of $310.13, suggesting a potential 12.77% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Moodys, with an average 1-year price target of $522.0, suggesting a potential 89.82% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Intercontinental Exchange, Coinbase Global and Moodys, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>CME Group</td>
<td>Neutral</td>
<td>10.38%</td>
<td>$1.44B</td>
<td>3.53%</td>
</tr>
<tr>
<td>Intercontinental Exchange</td>
<td>Outperform</td>
<td>15.28%</td>
<td>$1.78B</td>
<td>2.87%</td>
</tr>
<tr>
<td>Coinbase Global</td>
<td>Buy</td>
<td>24.23%</td>
<td>$1.53B</td>
<td>0.63%</td>
</tr>
<tr>
<td>Moodys</td>
<td>Outperform</td>
<td>7.73%</td>
<td>$1.43B</td>
<td>17.21%</td>
</tr>
</tbody>
</table>

Key Takeaway:
CME Group ranks in the middle among its peers for revenue growth, with a growth rate of 10.38%. It is at the bottom for gross profit at $1.44B. The company's return on equity is also below average at 3.53%. Overall, CME Group's performance is not leading in comparison to its peers in these key financial metrics.
<h3>Delving into CME Gr's Background</h3>
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&amp;P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&amp;P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
<h3>Financial Insights: CME Gr</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining CME Gr's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.38% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 57.49%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): CME Gr's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.53%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): CME Gr's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.64%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.13.
<a href="https://www.benzinga.com/quote/CME/earnings">To track all earnings releases for CME Gr visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: CME Gr's Earnings

The recent surge in high-beta stocks, including those in Jim Cramer&#8216;s &#8216;PARC&#8217; acronym, has raised concerns among analysts. JPMorgan&#8216;s strategist, Dubravko Lakos-Bujas, has issued a warning about the potential risks associated with this trend.
What Happened: The &#8220;PARC&#8221; stocks, a term coined by Cramer, are Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), Applovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>), Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), and Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>). These stocks are characterized by their momentum and tenuous links to traditional valuation metrics, as <a href="https://www.marketwatch.com/story/palantir-coinbase-and-these-other-volatile-stocks-are-too-crowded-says-jpmorgan-heres-the-trade-to-make-instead-363caad2">per</a> a MarketWatch report.
The bank has identified a group of high-beta stocks. The list includes two of Cramer's PARC picks, Palantir and Coinbase, along with retail investor favorites like Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) and Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Lakos-Bujas and his team at JPMorgan have pinpointed three occasions this year when investment style factors underwent &#8220;extreme crowding episodes.&#8221;&nbsp;They noted that the recent surge in high-beta stocks, which are more volatile than the market, is the fastest move from the 25th to the 100th percentile in three decades.
The latest episode, now at the 100th percentile, centers on high-beta stocks. The team believes that this overcrowding is not sustainable and poses a risk to the broader market. They also observed a decrease in short interest in high-beta stocks, suggesting that investors are not adequately hedged against potential selloffs.
&#8220;While&nbsp;some argue high-beta crowding could&nbsp;persist, we believe the current&nbsp;100%-tile crowding based on our&nbsp;quantitative analysis not only presents&nbsp;a risk for this crowded&nbsp;segment, but is also&nbsp;a red flag for the&nbsp;broader market implying there is&nbsp;rising complacency in the short&nbsp;term,&#8221; the JPMorgan team wrote.
As an alternative, the team suggests investors consider going long on&nbsp;Low Vol Aristocrats, which have&nbsp;underperformed the market by 19%&nbsp;since April 8.&nbsp;Their top five stocks in&nbsp;this category include&nbsp;Coca-Cola Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>),&nbsp;Allegion PLC&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLE#NYSE">ALLE</a>),&nbsp;Intercontinental Exchange Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>),&nbsp;CME Group Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>), and&nbsp;Cboe Global Markets Inc.&nbsp;(CBOE: CBOE).
SEE ALSO:&nbsp;<a href="https://benzinga.com/personal-finance/management/25/07/46514930/medicaid-cuts-in-3-democrat-led-states-strip-health-coverage-from-undocumented-immigr" target="_blank" rel="noreferrer noopener">Medicaid Cuts In 3 Democrat-Led States Strip Health Coverage From Undocumented Immigrants Amid Budget Crunch</a>
Why It Matters: The &#8216;PARC&#8217; stocks have been a hot topic in the market, with Cramer&#8217;s new acronym sparking discussions. The stocks have been performing well, with Coinbase hitting a&nbsp;<a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46408794/parc-stock-coinbase-hits-100-billion-market-capitalization-as-bitcoin-rally-powers-crypto-linked-equities">market capitalization</a> of $100 billion&nbsp;and Robinhood showing&nbsp;strong <a href="https://www.benzinga.com/markets/tech/25/07/46419665/cramers-parc-playbook-robinhoods-breakout-potential-outshines-the-meme-stock-pack">technical performance</a>.
Meanwhile, Tech bull Daniel Ives has unveiled his top five stock picks for the second half of 2025, reaffirming his view that the "golden age of tech" is underway, driven by the accelerating artificial intelligence (AI) revolution.
In a post on X, Ives named Nvidia, Palantir Technologies, Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Tesla as his top selections for the rest of the year.
However, JPMorgan&#8217;s warning about the potential risks associated with high-beta stocks could signal a shift in market sentiment. Investors may want to consider alternative strategies, such as low volatility stocks, which JPMorgan believes present an attractive risk/reward.
READ MORE:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46487074/overvalued-ai-stocks-like-nvidia-microsoft-may-trigger-market-crash-worse-than-the-dot-com-bubble-economist-warns">&#8216;Overvalued&#8217; AI Stocks Like Nvidia, Microsoft May Trigger Market Crash Worse Than The Dot-Com Bubble, Economist Warns </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

ALLE

CBOE

COIN

HOOD

MSFT

NVDA

PLTR

SMCI

Nvidia, Tesla And Few Of Jim Cramer's 'PARC' Stocks Are 'Red Flag' For Market, JPMorgan Warns: What's The Smarter Trade Instead?

Piper Sandler analyst Patrick Moley maintains CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) with a Overweight and raises the price target from $283 to $296.

Piper Sandler Maintains Overweight on CME Group, Raises Price Target to $296

Barclays analyst Benjamin Budish maintains CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) with a Equal-Weight and raises the price target from $283 to $299.

Barclays Maintains Equal-Weight on CME Group, Raises Price Target to $299

<ul>
<li>Record Europe, Middle East and Africa (EMEA) ADV of 6.7M, up 15% in Q2 2025</li>
<li>Record Asia Pacific (APAC) ADV of 2.2M, up 30% in Q2 2025</li>
</ul>

CME Group Reported Record 9.2M Average Daily Contracts Traded Outside US In Q2 2025, Up 18% Year Over Year

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $281.25, a high estimate of $305.00, and a low estimate of $211.00. This upward trend is evident, with the current average reflecting a 3.72% increase from the previous average price target of $271.17.
<img src="https://www.benzinga.com/files/images/story/2025/1751551233_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of CME Group by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$275.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$305.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$282.00</td>
<td>$279.00</td>
</tr>
<tr>
<td>Mike Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$304.00</td>
<td>$301.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$273.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$211.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$283.00</td>
<td>$279.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$279.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$301.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$283.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$279.00</td>
<td>$263.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CME Group. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CME Group compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CME Group's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CME/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CME Group analyst ratings.</a>
<h2>Unveiling the Story Behind CME Group</h2>
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&amp;P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&amp;P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
<h3>A Deep Dive into CME Group's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3M period, CME Group showcased positive performance, achieving a revenue growth rate of 10.38% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: CME Group's net margin excels beyond industry benchmarks, reaching 57.49%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): CME Group's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.53%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): CME Group's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.64%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: CME Group's debt-to-equity ratio is below the industry average at 0.13, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: CME Group In The Eyes Of 12 Experts

Citigroup analyst Christopher Allen maintains CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) with a Neutral and raises the price target from $265 to $275.

Citigroup Maintains Neutral on CME Group, Raises Price Target to $275

Looking into the current session, CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) shares are trading at $275.20, after a 0.08% decrease. Over the past month, the stock fell by 1.64%, but over the past year, it actually went up by 39.17%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1751468423_0.png" alt="Past Year Chart" />

<h3>Evaluating CME Group P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 33.77 in the Capital Markets industry, CME Group Inc. has a lower P/E ratio of 27.71. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1751468423_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for CME Group

CME Group Reports Record Q2 ADV Of 30.2M Contracts, Driven By Interest Rates, Agriculture, Metals, And SOFR Futures Growth









Ask ChatGPT

CME Group Unveils FX Tape+ To Deliver Centralized Reference Pricing From Transparent FX Marketplaces

William R Shepard, Director at CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>), disclosed an insider purchase on June 26, based on a new SEC filing.
What Happened: In a significant move reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001156375/000115637525000139//Archives/edgar/data/1156375/000115637525000139/0001156375-25-000139-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, Shepard purchased 1,146 shares of CME Group, demonstrating confidence in the company's growth potential. The total value of the transaction stands at $312,329.
During Friday's morning session, CME Group shares up by 0.37%, currently priced at $273.85.
<h3>Unveiling the Story Behind CME Group</h3>
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&amp;P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&amp;P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
<h3>A Deep Dive into CME Group's Financials</h3>
Revenue Growth: CME Group displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 10.38%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 87.41%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): CME Group's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 2.63.
</li>
</ul>
Debt Management: CME Group's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 27.45, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 15.63, CME Group's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 19.39, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001156375">Check Out The Full List Of CME Group's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Bullish Move: William R Shepard Shows Confidence, Acquires $312K In CME Group Stock

Press Releases

CME Group to Launch Futures on Mexico's IPC Index

CME Group Inc. Announces Second-Quarter 2025 Earnings Release, Conference Call

CME Group to Launch FTSE CoreCommodity CRB Futures on July 21

Fintech

CME Group to Launch FX Tape+ to Provide Centralized Reference Prices for the FX Market

Farmer sentiment weakens due to cloudy trade outlook

CME Group Sets Record Quarterly and June ADV, Driven by Growth Across Asset Classes

CME Group Completes First Delivery Cycle of Hard Red Spring Wheat Futures

CME Group International Average Daily Volume Hits Record 9.2 Million Contracts in Q2 2025, Up 18% Year over Year

CME Group and Nasdaq Extend Exclusive Nasdaq-100 Futures License Through 2039

CME Group Inc. Reports All-Time Record Revenue, Adjusted Operating Income, Adjusted Net Income and Adjusted Earnings Per Share for Q2 2025

NDAQ

AGM Group Holdings Inc. - Class A Ordinary Shares

AGM Group Holdings

Aether Holdings

Bakkt Holdings, Inc. Class A Common Stock

Bakkt Hldgs

Coincheck Group

Coinbase Global, Inc. - Class A Common Stock

Coinbase Global

Donnelley Financial Solutions, Inc. Common Stock

Donnelley Financial Solns

FactSet Research Systems Inc. Common Stock

FactSet Research Systems

Fold Holdings

Intercontinental Exchange Inc. Common Stock

Intercontinental Exchange

Open Lending

Moodys

Marketwise

MarketAxess Holdings, Inc. - Common Stock

MarketAxess Holdings

Morningstar

MSCI

Nasdaq

Powell Max Limited - Class A Ordinary Shares

Powell Max

S&P Global

Tradeweb Markets Inc. - Class A Common Stock

Tradeweb Markets

Value Line

Oppenheimer

Barclays

Piper Sandler

Citigroup

Screenshot 2024-12-12 at 6.46.22 PM

Some Anticipate A Bear Market In 2025, But Geopolitical Conflicts May Continue To Drive Gold Prices Higher – Time To Buy A Gold IRA?

Comments

CME Group

Noticias

Últimas noticias sobre CME Group (NASDAQ:CME) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL